Cormorant Asset Management, LP
13F Reported Value
ⓘ$2.0B
Holdings
50
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Cormorant Asset Management, LP disclosed 50 positions worth $2.0B in its Form 13F-HR for Q2 2026, led by $PRAX (Praxis Precision Medicines, Inc.) at 11.0% of the equity portfolio, followed by $BBOT and $PBLS. During the quarter the fund opened 12 new positions and exited 9 — including a new stake in $PBLS and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (93.6% of disclosed assets). All figures are sourced directly from Cormorant Asset Management, LP’s Form 13F-HR filing with the SEC under CIK 1583977.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $214.3M640,000 sh
- $136.2M17,878,594 sh
- —
Quality
$126.3M4,615,612 sh - —
Quality
$110.7M2,657,521 sh - —
Quality
$109.9M6,000,000 sh - —
Quality
$102.0M2,510,000 sh - 3.5
Quality
$100.1M7,000,000 sh - 7.1
Quality
$92.5M3,285,596 sh - —
Quality
$90.0M675,000 sh - 22.6
Quality
$73.1M750,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Praxis Precision Medicines, Inc.$PRAX | — | $214.3M | 640,000 |
 BridgeBio Oncology Therapeutics, Inc.$BBOT | — | $136.2M | 17,878,594 |
 Parabilis Medicines, Inc.$PBLS | — | $126.3M | 4,615,612 |
 Rapport Therapeutics, Inc.$RAPP | — | $110.7M | 2,657,521 |
 Erasca, Inc.$ERAS | — | $109.9M | 6,000,000 |
 Edgewise Therapeutics, Inc.$EWTX | — | $102.0M | 2,510,000 |
 EyePoint, Inc.$EYPT | 3.5 | $100.1M | 7,000,000 |
 ALUMIS INC.$ALMS | 7.1 | $92.5M | 3,285,596 |
 Abivax S.A.$ABVX | — | $90.0M | 675,000 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 22.6 | $73.1M | 750,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Cormorant Asset Management, LP's 50 positions.
Showing top 10 of 50 holdings.
Sector Allocation
Healthcare
$1.8B
Technology
$100.1M
Other
$21.5M
Financials
$4.0M
Full Holdings — Cormorant Asset Management, LP (Q2 2026)
All 50 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $214.3M | 11.0% | -28% | — |
| 2 | $BBOT | BridgeBio Oncology Therapeutics, Inc. | $136.2M | 7.0% | +0% | — |
| 3 | $PBLS | Parabilis Medicines, Inc. | $126.3M | 6.5% | NEW | — |
| 4 | $RAPP | Rapport Therapeutics, Inc. | $110.7M | 5.7% | -10% | — |
| 5 | $ERAS | Erasca, Inc. | $109.9M | 5.6% | +3% | — |
| 6 | $EWTX | Edgewise Therapeutics, Inc. | $102.0M | 5.2% | -23% | — |
| 7 | $EYPT | EyePoint, Inc. | $100.1M | 5.1% | -15% | 3.5 |
| 8 | $ALMS | ALUMIS INC. | $92.5M | 4.7% | -17% | 7.1 |
| 9 | $ABVX | Abivax S.A. | $90.0M | 4.6% | -11% | — |
| 10 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $73.1M | 3.8% | -21% | 22.6 |
| 11 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $63.2M | 3.2% | -15% | — |
| 12 |  $MLTX | MoonLake Immunotherapeutics | $62.4M | 3.2% | -28% | — |
| 13 |  $BIOA | BioAge Labs, Inc. | $58.6M | 3.0% | -17% | 26.8 |
| 14 |  $ORKA | Oruka Therapeutics, Inc. | $50.8M | 2.6% | +0% | — |
| 15 |  $ANL | Adlai Nortye Group Ltd. | $45.7M | 2.3% | +37% | — |
| 16 |  $BBIO | BridgeBio Pharma, Inc. | $41.0M | 2.1% | -35% | 36.9 |
| 17 |  $TNGX | Tango Therapeutics, Inc. | $40.6M | 2.1% | -9% | 17.6 |
| 18 |  $BHVN | Biohaven Ltd. | $38.8M | 2.0% | +48% | — |
| 19 |  $AGMB | Agomab Therapeutics NV | $32.0M | 1.6% | +0% | — |
| 20 |  $MBX | MBX Biosciences, Inc. | $30.4M | 1.6% | -51% | — |
| 21 |  $CLYM | Climb Bio, Inc. | $27.5M | 1.4% | NEW | — |
| 22 |  $OLMA | Olema Pharmaceuticals, Inc. | $26.9M | 1.4% | -45% | — |
| 23 |  $DMRA | Damora Therapeutics, Inc. | $26.0M | 1.3% | -34% | — |
| 24 |  $PHVS | Pharvaris N.V. | $25.9M | 1.3% | -25% | — |
| 25 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $22.0M | 1.1% | +0% | — |
| 26 |  $SYRE | Spyre Therapeutics, Inc. | $20.0M | 1.0% | NEW | — |
| 27 |  $DFTX | Definium Therapeutics, Inc. | $18.8M | 1.0% | NEW | — |
| 28 |  $NAMS | NewAmsterdam Pharma Co N.V. | $16.9M | 0.9% | -47% | — |
| 29 |  $ROIV | Roivant Sciences Ltd. | $16.8M | 0.9% | -37% | — |
| 30 |  $CABA | Cabaletta Bio, Inc. | $15.6M | 0.8% | -9% | — |
| 31 | — | HELIX ACQUISITION CORP III - USD CL A ORD SHS | $13.8M | 0.7% | +0% | — |
| 32 |  $ASND | Ascendis Pharma A/S | $13.3M | 0.7% | -47% | 44.8 |
| 33 |  $KLRA | Kailera Therapeutics, Inc. | $12.1M | 0.6% | NEW | — |
| 34 |  $INSM | INSMED Inc | $8.0M | 0.4% | -61% | 39.4 |
| 35 | — | FAETH THERAPEUTICS INC - COM NEW | $7.7M | 0.4% | +236% | — |
| 36 |  $ELVN | Enliven Therapeutics, Inc. | $7.6M | 0.4% | NEW | — |
| 37 |  $TARS | Tarsus Pharmaceuticals, Inc. | $6.3M | 0.3% | -56% | 55 |
| 38 |  $IBIO | iBio, Inc. | $6.2M | 0.3% | NEW | 10.4 |
| 39 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $4.7M | 0.2% | -50% | 25.5 |
| 40 |  $ARQT | Arcutis Biotherapeutics, Inc. | $4.6M | 0.2% | -61% | 62.9 |
| 41 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $4.1M | 0.2% | -50% | 38.7 |
| 42 |  $GPCR | Structure Therapeutics Inc. | $4.0M | 0.2% | -57% | — |
| 43 |  $RACC | Research Alliance Corp III | $4.0M | 0.2% | NEW | — |
| 44 |  $COGT | Cogent Biosciences, Inc. | $3.9M | 0.2% | -50% | — |
| 45 |  $ALT | Altimmune, Inc. | $3.8M | 0.2% | NEW | 8 |
| 46 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $3.6M | 0.2% | -43% | 8.7 |
| 47 |  $ODTX | Odyssey Therapeutics, Inc. | $3.3M | 0.2% | NEW | — |
| 48 |  $PCVX | Vaxcyte, Inc. | $2.9M | 0.1% | -50% | — |
| 49 |  $BOLD | Boundless Bio, Inc. | $2.5M | 0.1% | NEW | — |
| 50 |  $QNCX | Quince Therapeutics, Inc. | $100,009 | 0.0% | NEW | — |
New Positions (12)
$PBLS Parabilis Medicines, Inc.$126.3M$CLYM Climb Bio, Inc.$27.5M$SYRE Spyre Therapeutics, Inc.$20.0M$DFTX Definium Therapeutics, Inc.$18.8M$KLRA Kailera Therapeutics, Inc.$12.1M$ELVN Enliven Therapeutics, Inc.$7.6M$IBIO iBio, Inc.$6.2M$RACC Research Alliance Corp III$4.0M$ALT Altimmune, Inc.$3.8M$ODTX Odyssey Therapeutics, Inc.$3.3M$BOLD Boundless Bio, Inc.$2.5M$QNCX Quince Therapeutics, Inc.$100,009
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Cormorant Asset Management, LP including:
Track Cormorant Asset Management, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Cormorant Asset Management, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Cormorant Asset Management, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Cormorant Asset Management, LP (SEC CIK: 1583977), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Cormorant Asset Management, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.